MPEP § 608.05(c) — Submissions of Biological Sequence Listings (Annotated Rules)
§608.05(c) Submissions of Biological Sequence Listings
This page consolidates and annotates all enforceable requirements under MPEP § 608.05(c), including statutory authority, regulatory rules, examiner guidance, and practice notes. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.
Submissions of Biological Sequence Listings
This section addresses Submissions of Biological Sequence Listings. Primary authority: 37 CFR 1.821(a), 37 CFR 1.831(b), and 37 CFR 1.821. Contains: 3 requirements.
Key Rules
Sequence Listing Format
For applications filed before July 1, 2022, the sequence listing can be a “Sequence Listing” (as an ACSII plain text file in compliance with 37 CFR 1.821 – 1.824) submission must be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2420 et seq. for detailed information.
For applications filed on or after July 1, 2022, the sequence listing must be a “Sequence Listing XML” (as an XML file in compliance with 37 CFR 1.831 – 1.834) submission can be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2412 – 2419 for detailed information.
Sequence Listing Content
Applications disclosing nucleotide and/or amino acid sequences, as defined in 37 CFR 1.821(a) for applications filed before July 1, 2022 or as defined in 37 CFR 1.831(b) for applications filed on or after July 1, 2022, are required to provide the biological sequence information in a sequence listing.
Citations
| Primary topic | Citation |
|---|---|
| Sequence Listing Format | 37 CFR § 1.821 |
| Sequence Listing Content | 37 CFR § 1.821(a) |
| Sequence Listing Format | 37 CFR § 1.831 |
| Sequence Listing Content | 37 CFR § 1.831(b) |
| Sequence Listing Format | MPEP § 2412 |
| Sequence Listing Format | MPEP § 2420 |
Source Text from USPTO’s MPEP
This is an exact copy of the MPEP from the USPTO. It is here for your reference to see the section in context.
Official MPEP § 608.05(c) — Submissions of Biological Sequence Listings
Source: USPTO608.05(c) Submissions of Biological Sequence Listings [R-07.2022]
Applications disclosing nucleotide and/or amino acid sequences, as defined in 37 CFR 1.821(a) for applications filed before July 1, 2022 or as defined in 37 CFR 1.831(b) for applications filed on or after July 1, 2022, are required to provide the biological sequence information in a sequence listing.
For applications filed before July 1, 2022, the sequence listing can be a “Sequence Listing” (as an ACSII plain text file in compliance with 37 CFR 1.821–1.824) submission must be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2420et seq. for detailed information.
For applications filed on or after July 1, 2022, the sequence listing must be a “Sequence Listing XML” (as an XML file in compliance with 37 CFR 1.831–1.834) submission can be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2412–2419 for detailed information.